About CUREFIP.COM
CUREFIP.COM was founded in the summer of 2019 after a friend’s cat was diagnosed with Feline Infectious Peritonitis (FIP).
At the time, we learned how devastating this disease is for both cats and their owners. My friend loved their cat like a member of the family, and when two veterinarians told them that FIP was “untreatable,” it was a heartbreaking moment.
The only treatment option suggested was a steroid-based anti-inflammatory medication, which could only provide temporary relief and comfort rather than address the underlying disease.
I also had two cats of my own—Butter and Porky—and this experience made me deeply concerned about the possibility of FIP affecting them as well. (Their names, by the way, come from my love of cooking.)
Discovering GS-441524
A few weeks later, I met my friend again and immediately noticed that they seemed much more hopeful. They told me their cat’s condition had significantly improved.
The reason was an experimental antiviral treatment called GS-441524.
After starting this treatment, the cat’s symptoms began to improve. This discovery sparked our curiosity. We wanted to understand how effective this treatment really was and why veterinarians had said the disease was untreatable while this therapy appeared to be helping.
Research Into FIP Treatments
As we began researching the subject in depth, we quickly discovered that there were no officially approved treatments for FIP available at the time.
However, we also found that two promising experimental antiviral therapies—GC-376 and GS-441524—had shown encouraging results in clinical studies conducted in the United States and Europe.
GC-376 demonstrated initial effectiveness in some clinical trials. However, it was also reported that relapse rates could be relatively high, and in certain cases the treatment was not effective against recurrent infections.
GS-441524, on the other hand, was studied by a research group led by Dr. Niels Pedersen at the University of California, Davis.
Clinical studies showed that GS-441524 achieved improvement rates well above 80%, with relapse rates reported to be below 10%. Even in rare cases of relapse, additional treatment with GS-441524 was often successful.
These findings represented a major breakthrough in the treatment of FIP.
The Problem: Access to Treatment
Despite the promising results of GS-441524, efforts to bring the drug to market as an officially approved veterinary treatment did not progress quickly.
As a result, countless cats around the world continued to lose their lives to FIP—even though research suggested that treatment could be possible.
Many veterinarians were understandably cautious about prescribing experimental therapies due to limited information and the absence of officially approved products. In addition, it was often unclear where reliable and consistently manufactured GS-441524 could be obtained.
Our Mission
To help address this problem, we began working with veterinary clinics in China that had extensive experience treating FIP cases.
Through these collaborations, we were able to partner with two brands that agreed to supply GS-441524 for international buyers.
Initially, we worked with products from the brands Slayer and Hua Hua. While both showed promising results, we observed variations in product consistency.
Independent laboratory testing revealed that the concentration of the active ingredient could vary between 10–15 mg/ml across different batches.
Recognizing the importance of consistent quality, we focused on establishing stricter product selection standards and developing partnerships with reliable manufacturing partners.
Through these ongoing efforts, we have been able to provide more consistent and reliable products, helping cats around the world receive treatment.
Today, the number of cats benefiting from treatment continues to grow every day
Our Commitment to Quality
Our GS-441524 products are independently tested by internationally recognized laboratories to verify that the concentration, purity, and volume match the specifications listed in the product description.
We are committed to maintaining strict quality standards so that cat owners can have confidence in the products they receive.
In addition, we have established a global shipping network, allowing us to deliver treatments to most regions within three days.
Providing access to treatment for cats in need around the world is both a responsibility and a mission that we take great pride in.
If you want, I can also help you create a much more powerful “About Us” page designed specifically for conversions, which blends mission storytelling + scientific credibility + emotional resonance—a format used by many of the most successful FIP treatment organizations.